We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will ...

Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a ...

Harrow is a fast-growing ophthalmic pharma company focused on delivering eye care drugs. Click here to read more about HROW's ...

Harrow’s Q3 revenue grew 44% YoY to $49.3 million, supported by increased prescriptions for Vevye and Iheezo. High SG&A costs of $33.6 million in Q3 sustained Harrow’s net loss despite gross margin ...

Harrow Health, an eye care pharmaceutical company, announced Wednesday morning that Novartis agreed to sell five drugs approved by the Food and Drug Administration for up to $175 million. Harrow will ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Energy Transfer LP (NYSE:ET). “The pipes are a great business here, they really are,” he added. On the earnings front, Energy ...